Growth hormone treatment for neurologic symptoms of post‐acute sequelae of COVID‐19 DOI Creative Commons
Traver J. Wright, Melinda Sheffield‐Moore, Richard B. Pyles

et al.

Clinical and Translational Science, Journal Year: 2024, Volume and Issue: 17(6)

Published: June 1, 2024

Abstract Following SARS‐CoV‐2 infection, some patients develop lingering neurologic symptoms of post‐acute sequelae COVID‐19 (PASC) that commonly include fatigue and “brain fog.” PASC are also linked with reduced growth hormone (GH) secretion, but GH treatment has not been tested to relieve symptoms. We enrolled 13 adults peak stimulated secretion less than 10 ng/mL (glucagon stimulation) in a pilot study receive 9 months daily injections an additional 3 off‐treatment assessment. compared at baseline 12 assessed measures cognition, metabolism, body composition, physical performance over the first 6 treatment. Patient‐reported outcomes fatigue, quality life, sleep, mood were recorded timepoints 6, 9, months. was associated significantly improved scores for Brief Fatigue Inventory, Multidimensional Symptom Quality Life Assessment Growth Hormone Deficiency Adults, Profile Mood States, Beck Depression Inventory‐II, no significant change Pittsburgh Sleep Index. Six adjunct changes resting energy expenditure, or performance. Peak altered following altered.

Language: Английский

Review of the relationship between growth hormone and SARS-CoV-2 infection DOI
Yousef Rasmi, Kevser Kübra Kırboğa, Neda Roshanravan

et al.

Future Virology, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 15

Published: April 11, 2025

Language: Английский

Citations

0
Viral persistence in long COVID: Research advances and treatment strategies DOI Creative Commons
Shiyang Liu, Yuming Guo, Fu‐Sheng Wang

et al.

Infectious Diseases & Immunity, Journal Year: 2025, Volume and Issue: unknown

Published: April 28, 2025

Abstract Although the coronavirus disease 2019 (COVID-19) pandemic has ended, enduring health impacts of severe acute respiratory syndrome 2 (SARS-CoV-2) infection continue to garner global attention, as approximately 10% patients develop long COVID (post COVID-19 condition). The epidemiological characteristics and symptoms have been reported, various pathogenic hypotheses proposed. Recent evidence suggests that SARS-CoV-2 nucleic acids or fragments persist in some post-infection these are correlated with symptoms. This review focuses on clinical studies linking persistence symptoms, explores relationship between viral other etiological hypotheses, such immune dysregulation, vascular issues, coagulation dysfunction, microbiome dysbiosis, brainstem/vagus nerve signaling latent virus reactivation. Futhermore, treatment strategies for proposed based current trials antiviral modulation therapies. Understanding role pathogenesis is critical developing targeted therapies improving management this debilitating condition.

Language: Английский

Citations

0
Growth hormone treatment for neurologic symptoms of post‐acute sequelae of COVID‐19 DOI Creative Commons
Traver J. Wright, Melinda Sheffield‐Moore, Richard B. Pyles

et al.

Clinical and Translational Science, Journal Year: 2024, Volume and Issue: 17(6)

Published: June 1, 2024

Abstract Following SARS‐CoV‐2 infection, some patients develop lingering neurologic symptoms of post‐acute sequelae COVID‐19 (PASC) that commonly include fatigue and “brain fog.” PASC are also linked with reduced growth hormone (GH) secretion, but GH treatment has not been tested to relieve symptoms. We enrolled 13 adults peak stimulated secretion less than 10 ng/mL (glucagon stimulation) in a pilot study receive 9 months daily injections an additional 3 off‐treatment assessment. compared at baseline 12 assessed measures cognition, metabolism, body composition, physical performance over the first 6 treatment. Patient‐reported outcomes fatigue, quality life, sleep, mood were recorded timepoints 6, 9, months. was associated significantly improved scores for Brief Fatigue Inventory, Multidimensional Symptom Quality Life Assessment Growth Hormone Deficiency Adults, Profile Mood States, Beck Depression Inventory‐II, no significant change Pittsburgh Sleep Index. Six adjunct changes resting energy expenditure, or performance. Peak altered following altered.

Language: Английский

Citations

3